MarketBeat
16 May 2026, 00:14 UTC · 17w ago
Verdict
Headline takes no side. We score CRSP +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
CRISPR Therapeutics expects six pipeline assets across cardiovascular, autoimmune, oncology, and rare disease programs to generate data over the next 12 to 18 months.
So whatReadouts from six programs within 18 months represent a massive near-term catalyst that will define the company's pipeline valuation beyond its single approved product.
More positive than 98% of claims this week
CASGEVY has initiated over 500 patients, with a lag of two to three quarters before initiation translates into revenue recognition.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 91% of claims this week
CTX310 showed approximately 50% reductions in LDL cholesterol or triglycerides with a favorable early safety profile using lipid nanoparticle delivery.
More positive than 86% of claims this week
Zugo-cel demonstrated a nearly 70% complete response rate in oncology and is advancing in autoimmune diseases, potentially offering autologous-like efficacy with allogeneic economics.
More positive than 84% of claims this week
CRISPR Therapeutics has submitted for a pediatric label expansion for CASGEVY to include patients ages 5 and older.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
CEO reports momentum in CASGEVY rollout, expansion of the pipeline into new disease areas, and positive early data for cardiovascular programs.
More positive than 74% of ticker scores this week
Company is credited with executing well on the supply chain and commercial rollout of CASGEVY, with increasing patient initiations.
Near neutral — 91% of ticker scores this week are stronger
Bank of America is mentioned only as the host of the fireside chat.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
23h ago
+15.7%
Price agrees with the score
$56.00 vs $48.41 close before publication (May 15) · not market-adjusted
CRSP chart →
